Skip to main content
logo
  • Investment Strategies
    Overview

    Investment Options

    • Alternatives
    • Beta Strategies
    • Equities
    • Fixed Income
    • Global Liquidity
    • Multi-Asset Solutions

    Capabilities & Solutions

    • ETFs
    • Pension Strategy & Analytics
    • Global Insurance Solutions
    • Outsourced CIO
    • Sustainable investing
  • Insights
    Overview

    Market Insights

    • Market Insights Overview
    • Mid-Year Outlook 2024
    • Eye on the Market
    • Guide to the Markets
    • Guide to Alternatives
    • Market Updates
    • Guide to Investing in Asia
    • U.S. Policy Pulse Hub

    Portfolio Insights

    • Portfolio Insights Overview
    • Alternatives
    • Asset Class Views
    • Currency
    • Equity
    • ETF Perspectives
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing
    • Strategic Investment Advisory Group

    ETF Insights

    • ETF Insights overview
    • Guide to ETFs
    • ETF Perspectives
  • Resources
    Overview
    • Center for Investment Excellence Podcasts
    • Insights App
    • Library
    • Webcasts
    • Multimedia
    • Morgan Institutional
    • Investment Academy
  • About us
    Overview
    • Our Leadership Team
    • Spectrum: Our Investment Platform
  • Contact Us
  • English
  • Role
  • Country
Morgan Institutional
Search
Menu
Search
You are about to leave the site Close
J.P. Morgan Asset Management’s website and/or mobile terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan Asset Management isn’t responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan Asset Management name.
CONTINUE Go Back
  1. Smoot Hardly: the US-China trade war, prescription drug price legislation and the 2020 election

  • LinkedIn Twitter Facebook

Smoot Hardly

2019/05/13

Michael Cembalest

 

I now believe that prospects for a deal are only 50/50 given China's withdrawal of concessions. The economic impact of a growing tariff conflict on the US is modest, but the hit to earnings could be worse. The negative market reaction is in part a consequence of how high valuations became after the spring 2019 rally. Also, how new research on US prescription drug prices vs other countries affects the prospects for drug price legislation. We conclude with an updated ideological scorecard for 2020 Presidential candidates and their policies.

Continue reading

Listen to the audio file or subscribe to the podcast to get the latest updates.

LISTEN AND SUBSCRIBE TO MICHAEL CEMBALEST

In this podcast series, Michael Cembalest, Chairman of Market and Investment Strategy offers timely commentary on the economy, marekts and investment portfolios
 

Listen on Apple Podcasts

Subscribe to RSS Feed

Read more by michael cembalest

0903c02a825c2fec

  • China Market
  • Trade war
  • Eye on the Market
J.P. Morgan Asset Management

  • About us
  • Investment stewardship
  • Privacy policy
  • Cookie policy
  • Sitemap
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2025 JPMorgan Chase & Co. All rights reserved.